Gamma Delta Cells are perfect cell therapy candidates exhibiting both innate and adaptive immune functions. "Innate" in that Gamma Delta cells mirror the function of Natural Killer cells (NK) and "Adaptive" in the secretion of cytokines that drive a variety of immune reactions. These cells recognize a broad range of tumor antigens, are safe, and can be scaled for commercialization.

One of the challenges of Gamma Delta Cells represents a tiny percentage of the blood, necessitating expanding cell numbers to obtain a meaningful dose. Intellistem has developed a proprietary process that, in production runs, has yielded numbers to support the commercialization of a cell therapy product.

Advanced Cancer Treatment involves a combination of approaches and pharmaceutical interventions. Tumor-antigen targeting monoclonal antibodies (mAb) is an important component of cancer treatment.

Intellistem was the first to recognize the synergistic therapeutic impact of administering Gamma Delta Cells with specific antibodies. In-vitro and in-human studies showed that Gamma Delta Cells enhance Antibody-Dependent Cell-mediated Cytotoxicity (ADCC).

In exploratory clinical studies, the combination therapy of allogeneic activated Gamma-Delta-cells with an antibody brought remission to a B-cell lymphoma patient.